Ranolazine extended-release - Gilead Sciences

Drug Profile

Ranolazine extended-release - Gilead Sciences

Alternative Names: CVT 303; CVT 3041; KEG 1295; RAN D; Ran4; Ranexa; Ranolazine hydrochloride; RS 43285; RS 43285-003; RS 43285-193

Latest Information Update: 10 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syntex Pharmaceuticals International
  • Developer CV Therapeutics; Gilead Sciences; Kissei Pharmaceutical; Menarini; North Shore-Long Island Jewish Health System; Ohio State University; University of Rochester
  • Class Acetanilides; Anti-ischaemics; Ischaemic heart disorder therapies; Piperazines; Small molecules
  • Mechanism of Action Partial fatty acid oxidation inhibitors; Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris
  • Phase III Acute coronary syndromes; Atrial fibrillation; Type 2 diabetes mellitus
  • Phase II Amyotrophic lateral sclerosis; Aortic valve stenosis; Heart failure; Left ventricular hypertrophy; Long QT syndrome; Myocardial ischaemia; Myotonic dystrophy
  • Discontinued Intermittent claudication; Ventricular arrhythmias

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Jun 2018 Phase-II clinical trials in Amyotrophic lateral sclerosis in USA (PO) (NCT03472950)
  • 21 Mar 2018 Gilead Sciences plans a phase II trial for Amyotrophic Lateral Sclerosis in USA (NCT03472950)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top